A detailed history of Vanguard Group Inc transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,665,058 shares of ABOS stock, worth $4.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,665,058
Previous 1,839,552 9.49%
Holding current value
$4.4 Million
Previous $7.06 Million 4.53%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$2.97 - $4.64 $518,247 - $809,652
-174,494 Reduced 9.49%
1,665,058 $6.74 Million
Q4 2023

Feb 14, 2024

SELL
$1.86 - $4.48 $31,620 - $76,160
-17,000 Reduced 0.92%
1,839,552 $7.06 Million
Q3 2023

Nov 14, 2023

BUY
$4.15 - $9.72 $4.66 Million - $10.9 Million
1,121,700 Added 152.64%
1,856,552 $7.7 Million
Q2 2023

Aug 14, 2023

BUY
$3.59 - $6.59 $412 - $757
115 Added 0.02%
734,852 $3.53 Million
Q1 2023

May 15, 2023

BUY
$3.75 - $6.65 $70,875 - $125,685
18,900 Added 2.64%
734,737 $2.98 Million
Q4 2022

Feb 10, 2023

BUY
$4.81 - $6.8 $311,644 - $440,578
64,791 Added 9.95%
715,837 $3.87 Million
Q3 2022

Nov 14, 2022

BUY
$4.63 - $6.74 $70,686 - $102,899
15,267 Added 2.4%
651,046 $6.53 Million
Q2 2022

Aug 12, 2022

SELL
$3.08 - $4.88 $1.84 Million - $2.92 Million
-598,992 Reduced 48.51%
635,779 $2.99 Million
Q1 2022

May 13, 2022

BUY
$3.91 - $6.73 $2.66 Million - $4.58 Million
679,798 Added 122.49%
1,234,771 $4.83 Million
Q4 2021

Feb 14, 2022

SELL
$6.54 - $15.31 $5.04 Million - $11.8 Million
-769,925 Reduced 58.11%
554,973 $3.75 Million
Q3 2021

Nov 12, 2021

BUY
$14.5 - $20.28 $19.2 Million - $26.9 Million
1,324,898 New
1,324,898 $19.7 Million

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $107M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.